Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours(495 views) Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
Department of Clinical Medicine and Surgery, Federico II University of Naples, Via S. Pansini 5, 80131 Napoli, Italy
Biomorphologic and Functional Sciences, Federico II University of Naples, Naples, Italy
Internal Medicine, Second University of Naples, Naples, Italy
Gastroenterology and Digestive Endoscopy, Pellegrini Hospital, Naples ASL NA1, Italy
Oncological Immunology, Istituto Nazionale Tumori Fondazione G.Pascale - IRCCS, Naples, Italy
Biological Geological and Environmental Sciences, University of Sannio, Benevento, Italy
Interventional Unit, Azienda Dei Colli Hospital, Naples, Italy
Endocrinology, Istituto Nazionale Tumori Fondazione G.Pascale - IRCCS, Naples, Italy
References: Brandi, M.L., Gagel, R.F., Angeli, A., Guidelines for diagnosis and therapy of MEN type 1 and type 2 (2001) Journal of Clinical Endocrinology & Metabolism, 86, pp. 5658-567
Thakker, R.V., Newey, P.J., Walls, G.V., Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1) (2012) Journal of Clinical Endocrinology & Metabolism, 97, pp. 2990-3011
Triponez, F., Goudet, P., Dosseh, D., Is surgery beneficial for MEN1 patients with small (< or = 2 cm), non-functioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE (2006) World Journal of Surgery, 30, pp. 654-662
Falconi, M., Bartsch, D.K., Eriksson, B., ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors (2012) Neuroendocrinology, 95, pp. 120-134
Niina, Y., Fujimori, N., Nakamura, T., The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 (2012) Gut and Liver, 6, pp. 287-294
Jann, H., Denecke, T., Koch, M., Impact of octreotide LAR on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin (2013) Neuroendocrinology, 98, pp. 137-143
Rinke, A., Muller, H.H., Schade-Brittinger, C., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group (2009) Journal of Clinical Oncology, 27, pp. 4656-4663
Camera, L., Paoletta, S., Mollica, C., Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: Multidetector-row computed tomography vs. Endoscopic ultrasound (2011) La Radiologia Medica, 116, pp. 595-606
Rozen, S., Skaletsky, H., Primer3 on the WWW for general users and for biologist programmers (2000) Methods in Molecular Biology, 132, pp. 365-386
Eisenhauer, E.A., Therasse, P., Bogaerts, J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) (2009) European Journal of Cancer, 45, pp. 228-247
Modlin, I.M., Pavel, M., Kidd, M., Review article: SSA in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours (2010) Alimentary Pharmacology and Therapeutics, 31, pp. 169-188
Plöckinger, U., Rindi, G., Arnold, R., Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, pp. 394-424
Garland, J., Buscombe, J.R., Bouvier, C., Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: A 3-year experience (2003) Alimentary Pharmacology and Therapeutics, 17, pp. 437-444
Toumpanakis, C., Garland, J., Marelli, L., Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR (2009) Alimentary Pharmacology and Therapeutics, 30, pp. 733-740
Jensen, R.T., Cadiot, G., Brandi, M.L., ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes (2012) Neuroendocrinology, 95, pp. 98-119
Tomassetti, P., Migliori, M., Corinaldesi, R., Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR (2000) Alimentary Pharmacology and Therapeutics, 14, pp. 557-560
Ferolla, P., Faggiano, A., Grimaldi, F., Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses (2012) Journal of Endocrinological Investigation, 35, pp. 326-331
Burgess, J.R., Greenaway, T.M., Parameswaran, V., Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis (1999) Cancer, 86, pp. 2154-2159
Lourenco, Jr.D.M., Toledo, R.A., Coutinho, F.L., The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1 (2007) Clinics, 62, pp. 465-476
Pieterman, C.R., Schreinemakers, J.M., Koppeschaar, H.P., Multiple endocrine neoplasia type 1 (MEN1): Its manifestations and effect of genetic screening on clinical outcome (2009) Clinical Endocrinology, 70, pp. 575-581
Ramundo, V., Milone, F., Severino, R., Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients (2011) Hormone and Metabolic Research, 43, pp. 794-800
Grozinsky-Glasberg, S., Franchi, G., Teng, M., Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line (2008) Neuroendocrinology, 87, pp. 168-181
Yao, J.C., Phan, A.T., Chang, D.Z., Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study (2008) Journal of Clinical Oncology, 10, pp. 4311-4318
Faggiano, A., Ramundo, V., Dicitore, A., Everolimus is an active agent in medullary thyroid cancer: A clinical and in vitro study (2012) Journal of Cellular and Molecular Medicine, 16, pp. 1563-1572
Brandi, M. L., Gagel, R. F., Angeli, A., Guidelines for diagnosis and therapy of MEN type 1 and type 2 (2001) Journal of Clinical Endocrinology & Metabolism, 86, pp. 5658-567
Thakker, R. V., Newey, P. J., Walls, G. V., Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1) (2012) Journal of Clinical Endocrinology & Metabolism, 97, pp. 2990-3011
Eisenhauer, E. A., Therasse, P., Bogaerts, J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1. 1) (2009) European Journal of Cancer, 45, pp. 228-247
Modlin, I. M., Pavel, M., Kidd, M., Review article: SSA in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours (2010) Alimentary Pharmacology and Therapeutics, 31, pp. 169-188
Pl ckinger, U., Rindi, G., Arnold, R., Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, pp. 394-424
Jensen, R. T., Cadiot, G., Brandi, M. L., ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes (2012) Neuroendocrinology, 95, pp. 98-119
Burgess, J. R., Greenaway, T. M., Parameswaran, V., Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis (1999) Cancer, 86, pp. 2154-2159
Lourenco, Jr. D. M., Toledo, R. A., Coutinho, F. L., The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1 (2007) Clinics, 62, pp. 465-476
Pieterman, C. R., Schreinemakers, J. M., Koppeschaar, H. P., Multiple endocrine neoplasia type 1 (MEN1): Its manifestations and effect of genetic screening on clinical outcome (2009) Clinical Endocrinology, 70, pp. 575-581
Yao, J. C., Phan, A. T., Chang, D. Z., Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study (2008) Journal of Clinical Oncology, 10, pp. 4311-4318
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours